Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6991921 | 0.84 | MCHR1 (0.48) | MCHR1CYP2D6CYP2C9TSHRSMN1; SMN2 | |
| SCHEMBL6989825 | 0.84 | EBP (0.43) | MCHR1TMEM97TSHRRAB9A | |
| SCHEMBL6739625 | 0.84 | POLB (0.48) | MCHR1CYP2C9TSHRGAACA1 | |
| SCHEMBL6988443 | 0.83 | EBP (0.53) | MCHR1TMEM97KCNH2 | |
| SCHEMBL6733799 | 0.81 | FAAH (0.47) | DRD3MCHR1 | |
| SCHEMBL6995882 | 0.81 | DRD3 (0.52) | DRD3TMEM97CCR3 | |
| SCHEMBL6997410 | 0.80 | EBP (0.45) | MCHR1TMEM97TSHRGAAPOLB | |
| SCHEMBL6996059 | 0.78 | CCR3 (0.49) | DRD3TMEM97CYP2C9GAALMNA | |
| SCHEMBL7027091 | 0.78 | MCHR1 (0.49) | MCHR1TMEM97TSHRKCNH2 | |
| SCHEMBL6995153 | 0.78 | CCR3 (0.52) | MCHR1CYP2C9LMNACCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | DRD3 51/4885MCHR1 1346/4885TMEM97 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.